Cited by 885Genetic Neurodegenerative DiseasesMetabolism and Genetic DisordersMitochondrial Function and Pathology

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

Browne, Susan E., Bowling, Allen C., Macgarvey, Usha, Baik, M. Jay, Berger, Stephanie C., Muquit, Miratul M. K., Bird, Edward D., Beal, M. Flint·1997·Annals of Neurology

DOI 10.1002/ana.410410514

Open this paper in CoChat — free account

Abstract

The etiology of the selective neuronal death that occurs in Huntington's disease (HD) is unknown. Several lines of evidence implicate the involvement of energetic defects and oxidative damage in the disease process, including a recent study that demonstrated an interaction between huntingtin protein and the glycolytic enzyme glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH). Using spectrophotometric assays in postmortem brain tissue, we found evidence of impaired oxidative phosphorylation enzyme activities restricted to the basal ganglia in HD brain, while enzyme activities were unaltered in three regions relatively spared by HD pathology (frontal cortex, parietal cortex, and cerebellum). Citrate synthase‐corrected complex II‐III activity was markedly reduced in both HD caudate (−29%) and putamen (−67%), and complex IV activity was reduced in HD putamen (−62%). Complex I and GAPDH activities were unaltered in all regions examined. We also measured levels of the oxidative damage product 8‐hydroxydeoxyguanosine (OH 8 dG) in nuclear DNA, and superoxide dismutase (SOD) activity. OH 8 dG levels were significantly increased in HD caudate. Cytosolic SOD activity was slightly reduced in HD parietal cortex and cerebellum, whereas particulate SOD activity was unaltered in these regions. These results further support a role for metabolic dysfunction and oxidative damage in the pathogenesis of HD.

Integrity signals

Registry

Crossref · 10.1002/ana.410410514

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Self-citation
Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
Beal, M. F. (1992) · Annals of Neurology · doi:10.1002/ana.410310202 · Cited by 962
Self-citation
Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced
Novelli, A., Reilly, J. A., Lysko, P. G., & Henneberry, R. C. (1988) · Brain Research · doi:10.1016/0006-8993(88)90765-2 · Cited by 961
Mitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758
Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain
Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., & Beal, M. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340416 · Cited by 757
Self-citation
Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons
DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.-P., Carraway, R., Reeves, S. A., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90346-1 · Cited by 749
Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency
Bourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Péquignot, E., Munnich, A., & Rötig, A. (1995) · Nature Genetics · doi:10.1038/ng1095-144 · Cited by 730
PURIFICATION OF AMINE OXIDASE FROM BEEF PLASMA
Tabor, C. W., Tabor, H., & Rosenthal, S. M. (1954) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)65591-7 · Cited by 725

Show all 41 references

Research works printed but not linked: 1

Tabor CW, 1954, Amine oxidases, J Biol Chem, 208, 645

Sorted by citations

Items 201–300 of 883

Iron dysregulation in Huntington's disease
Müller, M., & Leavitt, B. R. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12739 · Cited by 123
Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells
Quintanilla, R. A., Jin, Y. N., Fuenzalida, K. M., Bronfman, M., & Johnson, G. V. W. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804291200 · Cited by 128
Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction
Goswami, A., Dikshit, P., Mishra, A., Mulherkar, S. A., Nukina, N., & Jana, N. R. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.136 · Cited by 124
Cystamine increases l ‐cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation
Fox, J. H., Barber, D. S., Singh, B., Zucker, B., Swindell, M. K., Norflus, F., Buzescu, R., Chopra, R., Ferrante, R. J., Kazantsev, A. G., et al. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02726.x · Cited by 123
Mutant Huntingtin: Nuclear translocation and cytotoxicity mediated by GAPDH
Bae, B.-I., Hara, M. R., Cascio, M. B., Wellington, C. L., Hayden, M. R., Ross, C. A., Ha, H. C., Li, X.-J., Snyder, S. H., & Sawa, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511316103 · Cited by 123
Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease
Shehadeh, J., Fernandes, H. B., Mullins, M. Z., Graham, R. K., Leavitt, B. R., Hayden, M. R., & Raymond, L. A. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.001 · Cited by 120
The role of excitotoxicity in neurodegeneration.
Salińska, E., Danysz, W., & Łazarewicz, J. W. (2005) · PubMed · Cited by 121
Huntingtin is a scaffolding protein in the ATM oxidative DNA damage response complex
Maiuri, T., Mocle, A. J., Hung, C. L.-K., Xia, J., van Roon‐Mom, W., & Truant, R. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw395 · Cited by 117
Neuroinflammation in Huntington’s Disease: A Starring Role for Astrocyte and Microglia
Saba, J., Couselo, F. L., Bruno, J., Carniglia, L., Durand, D., Lasaga, M., & Caruso, C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x19666211201094608 · Cited by 117
PGC-1α at the intersection of bioenergetics regulation and neuron function: From Huntington's disease to Parkinson's disease and beyond
Tsunemi, T., & Spada, A. R. L. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.10.004 · Cited by 119
Clinical correlation of striatal 1H MRS changes in Huntington’s disease
Sánchez‐Pernaute, R., García-Segura, J. M., Alba, A. D. B., Viano, J. C., & de Yébenes, J. G. (1999) · Neurology · doi:10.1212/wnl.53.4.806 · Cited by 113
A Dual Role of Adenosine A2AReceptors in 3-Nitropropionic Acid-Induced Striatal Lesions: Implications for the Neuroprotective Potential of A2AAntagonists
Blum, D. L., Galas, M., Pintor, A., Brouillet, E., Ledent, C. A., Müller, C. E., Bantubungi, K., Galluzzo, M., Gall, D., Cuvelier, L., et al. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-12-05361.2003 · Cited by 116
Mitochondrial permeability transition pore induces mitochondria injury in Huntington disease
Quintanilla, R. A., Jin, Y. N., von Bernhardi, R., & Johnson, G. V. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-45 · Cited by 108
Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters
Estrada‐Sánchez, A. M., Montiel, T., Segovia, J., & Massieu, L. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.12.017 · Cited by 113
Oxidative injury in the nervous system
Delanty, N., & Dichter, M. A. (1998) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb07285.x · Cited by 114
Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies
Ouary, S., Bizat, N., Altairac, S., Ménétrat, H., Mittoux, V., Condé, F., Hantraye, P., & Brouillet, E. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00020-8 · Cited by 111
Tissue Transglutaminase-Catalyzed Formation of High-Molecular-Weight Aggregatesin VitroIs Favored with Long Polyglutamine Domains: A Possible Mechanism Contributing to CAG-Triplet Diseases
Gentile, V., Sepe, C., Calvani, M., Melone, M. A. B., Cotrufo, R., Cooper, A. J. L., Blass, J. P., & Peluso, G. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0592 · Cited by 108
Environmental factors as modulators of neurodegeneration: Insights from gene–environment interactions in Huntington's disease
Mo, C., Hannan, A. J., & Renoir, T. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.003 · Cited by 108
Does Vitamin C Deficiency Affect Cognitive Development and Function?
Hansen, S. L., Tveden‐Nyborg, P., & Lykkesfeldt, J. (2014) · Nutrients · doi:10.3390/nu6093818 · Cited by 111
Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission
Reddy, P. H. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.020 · Cited by 109
Tauroursodeoxycholic Acid Partially Prevents Apoptosis Induced by 3‐Nitropropionic Acid
Rodrigues, C. M. P., Linehan-Stieers, C., Keene, C. D., Ma, X., Kren, B. T., Low, W. C., & Steer, C. J. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752368.x · Cited by 104
Huntington Disease and the Huntingtin Protein
Zheng, Z., & Diamond, M. I. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00010-2 · Cited by 118
Therapeutic potential of N-acetylcysteine in age-related mitochondrial neurodegenerative diseases
Banaclocha, M. M. (2001) · Medical Hypotheses · doi:10.1054/mehy.2000.1194 · Cited by 104
In Vitro and in Vivo Aggregation of a Fragment of Huntingtin Protein Directly Causes Free Radical Production
Hands, S. L., Sajjad, M. U., Newton, M. J., & Wyttenbach, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.307587 · Cited by 106
Mitochondrial DNA, base excision repair and neurodegeneration
de Souza-Pinto, N. C., Wilson, D. M., Stevnsner, T., & Bohr, V. A. (2008) · DNA repair · doi:10.1016/j.dnarep.2008.03.011 · Cited by 102
Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling
Tatton, W. G., Chalmers-Redman, R. M. E., Elstner, M., Leesch, W., Jagodzinski, F. B., Stupak, D. P., Sugrue, M. M., & Tatton, N. A. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_5 · Cited by 105
The Mitochondrial Toxin 3-Nitropropionic Acid Induces Striatal Neurodegeneration via a c-Jun N-Terminal Kinase/c-Jun Module
García, M., Vanhoutte, P., Pagès, C., Besson, M., Brouillet, E., & Caboche, J. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02174.2002 · Cited by 102
The Role of Mitochondria in the Pathogenesis of Neurodegenerative Diseases
Manfredim, G., & Beal, M. F. (2000) · Brain Pathology · doi:10.1111/j.1750-3639.2000.tb00278.x · Cited by 101
Self-citation
Overexpression of copper/zinc superoxide dismutase does not prevent neonatal lethality in mutant mice that lack manganese superoxide dismutase
Copin, J., Gasche, Y., & Chan, P. H. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00280-x · Cited by 106
Bioenergetics in Huntington's Disease
Grünewald, T. G. P., & Beal, M. F. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07827.x · Cited by 100
Self-citation
Huntington Disease and the Related Disorder, Dentatorubral-Pallidoluysian Atrophy (DRPLA)
Ross, C. A., Margolis, R. L., Rosenblatt, A., Ranen, N. G., Bêcher, M. W., & Aylward, E. (1997) · Medicine · doi:10.1097/00005792-199709000-00001 · Cited by 101
Anti-death properties of TNF against metabolic poisoning: mitochondrial stabilization by MnSOD
Bruce‐Keller, A. J., Geddes, J. W., Knapp, P. E., McFall, R. W., Keller, J. N., Holtsberg, F. W., Parthasarathy, S., Steiner, S. M., & Mattson, M. P. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00190-8 · Cited by 99
The role of oxidative stress in Huntington’s disease: Are antioxidants good therapeutic candidates?
Gil-Mohapel, J., Brocardo, P., & Christie, B. (2014) · Current Drug Targets · doi:10.2174/1389450115666140115113734 · Cited by 101
Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons
Petersén, Å., Castilho, R. F., Hansson, O., Wieloch, T. W., & Brundin, P. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02320-3 · Cited by 99
Oxidative damage to the promoter region of SQSTM1/p62 is common to neurodegenerative disease
Du, Y., Wooten, M. C., & Wooten, M. W. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.015 · Cited by 96
Clinical correlates of mitochondrial function in Huntington's disease muscle
Turner, C., Cooper, J. M., & Schapira, A. H. V. (2007) · Movement Disorders · doi:10.1002/mds.21540 · Cited by 97
DNA breakage and induction of DNA damage response proteins precede the appearance of visible mutant huntingtin aggregates
Illuzzi, J. L., Yerkes, S., Parekh‐Olmedo, H., & Kmiec, E. B. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21881 · Cited by 98
D-β-Hydroxybutyrate Is Protective in Mouse Models of Huntington's Disease
Lim, S., Chesser, A. S., Grima, J. C., Rappold, P. M., Blum, D. L., Przedborski, S., & Tieu, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024620 · Cited by 94
Role of cerebral cortex in the neuropathology of Huntington's disease
Estrada‐Sánchez, A. M., & Rebec, G. V. (2013) · Frontiers in Neural Circuits · doi:10.3389/fncir.2013.00019 · Cited by 96
Dysregulation of Mitochondrial Calcium Signaling and Superoxide Flashes Cause Mitochondrial Genomic DNA Damage in Huntington Disease
Wang, J., Chen, Q., Wang, X., Wang, Q.-C., Wang, Y., Cheng, H., Guo, C., Sun, Q., Chen, Q., & Tang, T.-S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.407726 · Cited by 92
Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway
Ruan, Q. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh082 · Cited by 93
Formation of Highly Reactive γ-Ketoaldehydes (Neuroketals) as Products of the Neuroprostane Pathway
Bernoud‐Hubac, N., Davies, S. S., Boutaud, O. G., Montine, T. J., & Roberts, L. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103768200 · Cited by 93
Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and α-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length
Cooper, A. J. L., Sheu, K. ‐. R., Burke, J. R., Onodera, O., Strittmatter, W. J., Roses, A. D., & Blass, J. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12604 · Cited by 92
Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Dadhania, V. P., Trivedi, P. P., Vikram, A., & Tripathi, D. N. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160104142223 · Cited by 93
Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington's disease mutation.
Pérez-Severiano, F., Escalante, B., Vergara, P., Ríos, C., & Segovia, J. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03102-5 · Cited by 95
Synaptic Activity and Bioenergy Homeostasis: Implications in Brain Trauma and Neurodegenerative Diseases
Khatri, N., & Man, H. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00199 · Cited by 96
Safety and tolerability of high‐dosage coenzyme Q10 in Huntington's disease and healthy subjects
The Huntington Study Group Pre2CARE Investigators (2010) · Movement Disorders · doi:10.1002/mds.22408 · Cited by 91
N-Acetylcysteine Reverses Mitochondrial Dysfunctions and Behavioral Abnormalities in 3-Nitropropionic Acid-Induced Huntington’s Disease
Sandhir, R., Sood, A., Mehrotra, A., & Kamboj, S. S. (2012) · Neurodegenerative Diseases · doi:10.1159/000334273 · Cited by 90
Cytopathies involving mitochondrial complex II
Ackrell, B. A. C. (2002) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(02)00012-2 · Cited by 86
Mitochondria in Multiple Sclerosis: Molecular Mechanisms of Pathogenesis
Patergnani, S., Fossati, V., Bonora, M., Giorgi, C., Marchi, S., Missiroli, S., Rusielewicz, T., Wieckowski, M. R., & Pinton, P. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.08.003 · Cited by 86
Modifiers of CAG/CTG Repeat Instability: Insights from Mammalian Models
Wheeler, V. C., & Dion, V. (2021) · Journal of Huntington s Disease · doi:10.3233/jhd-200426 · Cited by 88
Disruption of Rab11 activity in a knock-in mouse model of Huntington's disease
Li, X., Sapp, E., Chase, K., Comer-Tierney, L. A., Masso, N., Alexander, J., Reeves, P., Kegel, K. B., Valencia, A., Esteves, M., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.08.003 · Cited by 87
The role of mitochondrial OXPHOS dysfunction in the development of neurologic diseases
Breuer, M. E., Koopman, W. J. H., Koene, S., Nooteboom, M., Rodenburg, R. J., Willems, P. H. G. M., & Smeitink, J. A. M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.007 · Cited by 87
Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation
Fain, J. N. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.2.145 · Cited by 87
The role of glutamate and its receptors in multiple sclerosis
Stojanović, I. R., Kostić, M. S., & Ljubisavljević, S. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1188-0 · Cited by 86
Mitochondrial permeability transition in neuronal damage promoted by Ca2+ and respiratory chain complex II inhibition
Maciel, E. N., Kowaltowski, A. J., Schwalm, F. D., Rodrigues, J. M., Souza, D. O., Vercesi, A. E., Wajner, M., & Castilho, R. F. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02565.x · Cited by 82
Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel
Wojtovich, A. P., Smith, C. O., Haynes, C. M., Nehrke, K. W., & Brookes, P. S. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.12.007 · Cited by 86
Antioxidative defense mechanisms controlled by Nrf2: state-of-the-art and clinical perspectives in neurodegenerative diseases
Lim, J. L., Wilhelmus, M. M. M., de Vries, H. E., Drukarch, B., Hoozemans, J. J. M., & van Horssen, J. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1338-z · Cited by 84
Mitochondria and Energetic Depression in Cell Pathophysiology
Seppet, E. K., Puurand, M., Peetsalu, A., Gizatullina, Z. Z., Nguyen, H. P., Vielhaber, S., Wussling, M. H. P., Trumbeckaitė, S., Arandarčikaitė, O., Jerzembek, D., et al. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10052252 · Cited by 84
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment
Schifitto, G., Zhang, J., Evans, S. R., Sacktor, N. C., Simpson, D. M., Millar, L., Hung, V., Miller, E. N., Smith, E. V., Ellis, R. J., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000268487.78753.0f · Cited by 86
Mitochondrial lipids in neurodegeneration
Aufschnaiter, A., Kohler, V., Diessl, J., Peselj, C., Carmona‐Gutiérrez, D., Keller, W., & Büttner, S. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2463-1 · Cited by 91
1H NMR based metabolomics of CSF and blood serum: A metabolic profile for a transgenic rat model of Huntington disease
Verwaest, K. A., Vu, T. N., Laukens, K., Clemens, L. E., Nguyen, H. P., Gasse, B. V., Martins, J. C., der Linden, A. V., & Dommisse, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.001 · Cited by 83
Mitochondrial NAD+‐linked State 3 respiration and complex‐I activity are compromised in the cerebral cortex of 3‐nitropropionic acid‐induced rat model of Huntington’s disease
Pandey, M., Varghese, M., Madathil, S. K., Sreetama, S. C., Kaidery, N. A., Mohanakumar, K. P., & Rajamma, U. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04996.x · Cited by 83
Can malondialdehyde be used as a biological marker of progression in neurodegenerative disease?
Dib, M., Garrel, C., Favier, A. E., Robin, V., & Desnuelle, C. (2002) · Journal of Neurology · doi:10.1007/s004150200025 · Cited by 84
8-OHdG in Cerebrospinal Fluid as a Marker of Oxidative Stress in Various Neurodegenerative Diseases
Gmitterová, K., Heinemann, U., Gawinecka, J., Varges, D., Ciesielczyk, B., Valkovič, P., Benetin, J., & Zerr, I. (2009) · Neurodegenerative Diseases · doi:10.1159/000237221 · Cited by 83
Huntington's Disease Induced Cardiac Amyloidosis Is Reversed by Modulating Protein Folding and Oxidative Stress Pathways in the Drosophila Heart
Melkani, G. C., Trujillo, A. S., Ramos, R., Bodmer, R., Bernstein, S. I., & Ocorr, K. A. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1004024 · Cited by 82
Treating neurodegeneration by modifying mitochondria: potential solutions to a “complex” problem
Swerdlow, R. H. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1676 · Cited by 81
Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation
Zourlidou, A., Gidalevitz, T., Kristiansen, M., Landles, C., Woodman, B., Wells, D. J., Latchman, D. S., de Belleroche, J., Tabrizi, S. J., Morimoto, R. I., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm057 · Cited by 82
Brain networks in Huntington disease
Eidelberg, D., & Surmeier, D. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45646 · Cited by 83
Alteration of Intracellular Structure and Function of Glyceraldehyde-3-Phosphate Dehydrogenase: A Common Phenotype of Neurodegenerative Disorders?
Mazzola, J. L., & Sirover, M. A. (2002) · NeuroToxicology · doi:10.1016/s0161-813x(02)00062-1 · Cited by 79
A ketogenic diet delays weight loss and does not impair working memory or motor function in the R6/2 1J mouse model of Huntington's disease
Ruskin, D. N., Ross, J. L., Kawamura, M., Ruiz, T., Geiger, J. D., & Masino, S. A. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.04.001 · Cited by 78
Coenzyme Q treatment of neurodegenerative diseases of aging
Galpern, W. R., & Cudkowicz, M. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.01.004 · Cited by 78
Coenzyme Q10 a mitochondrial restorer for various brain disorders
Pradhan, N., Singh, C., & Singh, A. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02161-8 · Cited by 79
The excitatory neurotransmitter glutamate stimulates DNA repair to increase neuronal resiliency
Yang, J., Sýkora, P., Wilson, D. M., Mattson, M. P., & Bohr, V. A. (2011) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2011.06.005 · Cited by 81
3-Nitropropionic acid-induced hydrogen peroxide, mitochondrial DNA damage, and cell death are attenuated by Bcl-2 overexpression in PC12 cells
Mandavilli, B. S., Boldogh, I. R., & Houten, B. V. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.10.033 · Cited by 77
Modeling Huntington's Disease in Cells, Flies, and Mice
Cattaneo, E. F., & Sipione, S. (2001) · Molecular Neurobiology · doi:10.1385/mn:23:1:21 · Cited by 79
Mitochondrial division inhibitor 1 protects against mutant huntingtin-induced abnormal mitochondrial dynamics and neuronal damage in Huntington's disease
Mańczak, M., & Reddy, P. H. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv429 · Cited by 77
Huntington?s disease: pathomechanism and therapeutic perspectives
G�rdi�n, G., & V�csei, L. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0201-4 · Cited by 76
Flexible Nets of Malleable Guardians: Intrinsically Disordered Chaperones in Neurodegenerative Diseases
Uversky, V. N. (2010) · Chemical Reviews · doi:10.1021/cr100186d · Cited by 75
Neuroprotective Effect of Lutein Against 3-Nitropropionic Acid–Induced Huntington's Disease–Like Symptoms: Possible Behavioral, Biochemical, and Cellular Alterations
Binawade, Y., & Jagtap, A. G. (2013) · Journal of Medicinal Food · doi:10.1089/jmf.2012.2698 · Cited by 75
Impaired Redox Signaling in Huntington’s Disease: Therapeutic Implications
Paul, B. D., & Snyder, S. H. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00068 · Cited by 76
Cytochrome c Oxidase and Its Role in Neurodegeneration and Neuroprotection
Arnold, S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3573-0_13 · Cited by 77
Understanding the Multiple Role of Mitochondria in Parkinson’s Disease and Related Disorders: Lesson From Genetics and Protein–Interaction Network
Nicoletti, V., Palermo, G., Prete, E. D., Mancuso, M., & Ceravolo, R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.636506 · Cited by 75
Oxidative injury in epilepsy: potential for antioxidant therapy?
Costello, D. J., & Delanty, N. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.3.541 · Cited by 74
Cystamine and cysteamine prevent 3‐NP‐induced mitochondrial depolarization of Huntington's disease knock‐in striatal cells
Mao, Z., Choo, Y. S., & Lesort, M. J. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04686.x · Cited by 75
Mitochondrial Abnormalities and Synaptic Damage in Huntington’s Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics
Sawant, N. A., Morton, H., Kshirsagar, S., Reddy, A. P., & Reddy, P. H. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02556-x · Cited by 74
Defective mitochondrial disulfide relay system, altered mitochondrial morphology and function in Huntington's disease
Napoli, E., Wong, S., Hung, C., Ross‐Inta, C., Bomdica, P. R., & Giulivi, C. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds503 · Cited by 72
Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II
Benchoua, A., Trioulier, Y., Diguet, E., Malgorn, C., Gaillard, M., Dufour, N., Elalouf, J., Krajewski, S., Hantraye, P., Déglon, N., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn033 · Cited by 72
Plants and phytochemicals for Huntington′s disease
Malik, J., Choudhary, S., & Kumar, P. (2013) · Pharmacognosy Reviews/Bioinformatics Trends/Pharmacognosy review · doi:10.4103/0973-7847.120505 · Cited by 74
The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders
Olesen, M. A., Villavicencio-Tejo, F., & Quintanilla, R. A. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00308-y · Cited by 80
Increased glucose metabolism and ATP level in brain tissue of Huntington’s disease transgenic mice
Oláh, J., Klivènyi, P., Gárdián, G., Vécsei, L., Orosz, F., Kovács, G. G., Westerhoff, H. V., & Ovádi, J. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06612.x · Cited by 71
Low stability of huntington muscle Mitochondria against Ca2+ in R6/2 mice
Gizatullina, Z. Z., Lindenberg, K. S., Harjes, P., Chen, Y., Kosinski, C. M., Landwehrmeyer, G. B., Ludolph, A. C., Striggow, F., Zierz, S., & Gellerich, F. N. (2006) · Annals of Neurology · doi:10.1002/ana.20754 · Cited by 72
Chrysin exerts neuroprotective effects against 3-Nitropropionic acid induced behavioral despair—Mitochondrial dysfunction and striatal apoptosis via upregulating Bcl-2 gene and downregulating Bax—Bad genes in male wistar rats
Sumathi, T., Ramachandran, S., & Krishnamurthy, P. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.09.070 · Cited by 72
Pathogenesis of Inclusion Bodies in (CAG)n/Qn‐Expansion Diseases with Special Reference to the Role of Tissue Transglutaminase and to Selective Vulnerability
Cooper, A. J. L., Sheu, K. R., Burke, J. R., Strittmatter, W. J., Gentile, V., Peluso, G., & Blass, J. P. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720889.x · Cited by 72
Iron and Neurodegeneration: From Cellular Homeostasis to Disease
Batista-Nascimento, L. S., Pimentel, C., Menezes, R., & Rodrigues‐Pousada, C. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/128647 · Cited by 74
8OHdG as a marker for Huntington disease progression
Long, J. D., Matson, W. R., Juhl, A. R., Leavitt, B. R., & Paulsen, J. S. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.02.012 · Cited by 71
Therapeutic Applications and Mechanisms of Superoxide Dismutase (SOD) in Different Pathogenesis
Anwar, S., Sarwar, T., Khan, A. A., & Rahmani, A. H. (2025) · Biomolecules · doi:10.3390/biom15081130 · Cited by 87
Complex I Is Rate-limiting for Oxygen Consumption in the Nerve Terminal
Telford, J. E., Kilbride, S. M., & Davey, G. P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809101200 · Cited by 70
Impaired mitochondrial trafficking in Huntington's disease
Li, X., Orr, A. L., & Li, S. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.06.008 · Cited by 70
Mitochondrial impairments contribute to Spinocerebellar ataxia type 1 progression and can be ameliorated by the mitochondria-targeted antioxidant MitoQ
Stucki, D., Ruegsegger, C., Steiner, S., Radecke, J., Murphy, M. P., Zuber, B., & Saxena, S. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.07.005 · Cited by 73

Authors: Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F.
Affiliations: Harvard University (US)
McLean Hospital (US)
Corresponding author: Beal, M. Flint
ORCID: Browne, Susan E.
Beal, M. Flint
Venue: Annals of Neurology
Publisher: Wiley
Published: 1997-05
Volume: 41
Issue: 5
Pages: 646-653
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.410410514
OpenAlex: W2102430316
Cited by: 885
References: 41
Citations by year: 2026: 14 · 2025: 12 · 2024: 18 · 2023: 17 · 2022: 25 · 2021: 33 · 2020: 22 · 2019: 18 · 2018: 31 · 2017: 13 · 2016: 47 · 2015: 31 · 2014: 41 · 2013: 37 · 2012: 46
FWCI: 10.37
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2717 d)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords: Huntington's disease, oxidative damage, metabolic dysfunction, basal ganglia, selective neuronal vulnerability, oxidative phosphorylation, complex IV activity, complex I, glyceraldehyde-3-phosphate dehydrogenase, huntingtin, 8-hydroxy-2'-deoxyguanosine, superoxide dismutase, caudate nucleus, putamen, postmortem brain
MeSH terms: Basal Ganglia, Cerebellum, Cerebral Cortex, DNA, Glyceraldehyde-3-Phosphate Dehydrogenases, Humans, Huntington Disease, Mitochondria, Oxidation-Reduction, Reference Values, Spectrophotometry, Stress, Physiological, Superoxide Dismutase, NAD(P)H Dehydrogenase (Quinone), In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks